Cargando…

Coenzyme Q10 for the treatment of heart failure: a review of the literature

Coenzyme Q10 (CoQ10) is an endogenously synthesised and diet-supplied lipid-soluble cofactor that functions in the mitochondrial inner membrane to transfer electrons from complexes I and II to complex III. In addition, its redox activity enables CoQ10 to act as a membrane antioxidant. In patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: DiNicolantonio, James J, Bhutani, Jaikrit, McCarty, Mark F, O'Keefe, James H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620231/
https://www.ncbi.nlm.nih.gov/pubmed/26512330
http://dx.doi.org/10.1136/openhrt-2015-000326
_version_ 1782397251494084608
author DiNicolantonio, James J
Bhutani, Jaikrit
McCarty, Mark F
O'Keefe, James H
author_facet DiNicolantonio, James J
Bhutani, Jaikrit
McCarty, Mark F
O'Keefe, James H
author_sort DiNicolantonio, James J
collection PubMed
description Coenzyme Q10 (CoQ10) is an endogenously synthesised and diet-supplied lipid-soluble cofactor that functions in the mitochondrial inner membrane to transfer electrons from complexes I and II to complex III. In addition, its redox activity enables CoQ10 to act as a membrane antioxidant. In patients with congestive heart failure, myocardial CoQ10 content tends to decline as the degree of heart failure worsens. A number of controlled pilot trials with supplemental CoQ10 in heart failure found improvements in functional parameters such as ejection fraction, stroke volume and cardiac output, without side effects. Subsequent meta-analyses have confirmed these findings, although the magnitude of benefit tends to be less notable in patients with severe heart failure, or within the context of ACE inhibitor therapy. The multicentre randomised placebo-controlled Q-SYMBIO trial has assessed the impact of supplemental CoQ10 on hard endpoints in heart failure. A total of 420 patients received either CoQ10 (100 mg three times daily) or placebo and were followed for 2 years. Although short-term functional endpoints were not statistically different in the two groups, CoQ10 significantly reduced the primary long-term endpoint—a major adverse cardiovascular event—which was observed in 15% of the treated participants compared to 26% of those receiving placebo (HR=0.50, CI 0.32 to 0.80, p=0.003). Particularly in light of the excellent tolerance and affordability of this natural physiological compound, supplemental CoQ10 has emerged as an attractive option in the management of heart failure, and merits evaluation in additional large studies.
format Online
Article
Text
id pubmed-4620231
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46202312015-10-28 Coenzyme Q10 for the treatment of heart failure: a review of the literature DiNicolantonio, James J Bhutani, Jaikrit McCarty, Mark F O'Keefe, James H Open Heart Review Coenzyme Q10 (CoQ10) is an endogenously synthesised and diet-supplied lipid-soluble cofactor that functions in the mitochondrial inner membrane to transfer electrons from complexes I and II to complex III. In addition, its redox activity enables CoQ10 to act as a membrane antioxidant. In patients with congestive heart failure, myocardial CoQ10 content tends to decline as the degree of heart failure worsens. A number of controlled pilot trials with supplemental CoQ10 in heart failure found improvements in functional parameters such as ejection fraction, stroke volume and cardiac output, without side effects. Subsequent meta-analyses have confirmed these findings, although the magnitude of benefit tends to be less notable in patients with severe heart failure, or within the context of ACE inhibitor therapy. The multicentre randomised placebo-controlled Q-SYMBIO trial has assessed the impact of supplemental CoQ10 on hard endpoints in heart failure. A total of 420 patients received either CoQ10 (100 mg three times daily) or placebo and were followed for 2 years. Although short-term functional endpoints were not statistically different in the two groups, CoQ10 significantly reduced the primary long-term endpoint—a major adverse cardiovascular event—which was observed in 15% of the treated participants compared to 26% of those receiving placebo (HR=0.50, CI 0.32 to 0.80, p=0.003). Particularly in light of the excellent tolerance and affordability of this natural physiological compound, supplemental CoQ10 has emerged as an attractive option in the management of heart failure, and merits evaluation in additional large studies. BMJ Publishing Group 2015-10-19 /pmc/articles/PMC4620231/ /pubmed/26512330 http://dx.doi.org/10.1136/openhrt-2015-000326 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
DiNicolantonio, James J
Bhutani, Jaikrit
McCarty, Mark F
O'Keefe, James H
Coenzyme Q10 for the treatment of heart failure: a review of the literature
title Coenzyme Q10 for the treatment of heart failure: a review of the literature
title_full Coenzyme Q10 for the treatment of heart failure: a review of the literature
title_fullStr Coenzyme Q10 for the treatment of heart failure: a review of the literature
title_full_unstemmed Coenzyme Q10 for the treatment of heart failure: a review of the literature
title_short Coenzyme Q10 for the treatment of heart failure: a review of the literature
title_sort coenzyme q10 for the treatment of heart failure: a review of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620231/
https://www.ncbi.nlm.nih.gov/pubmed/26512330
http://dx.doi.org/10.1136/openhrt-2015-000326
work_keys_str_mv AT dinicolantoniojamesj coenzymeq10forthetreatmentofheartfailureareviewoftheliterature
AT bhutanijaikrit coenzymeq10forthetreatmentofheartfailureareviewoftheliterature
AT mccartymarkf coenzymeq10forthetreatmentofheartfailureareviewoftheliterature
AT okeefejamesh coenzymeq10forthetreatmentofheartfailureareviewoftheliterature